Wednesday, July 8, 2026

Patent intelligence · US

US 11312756

Engineered potent cytotoxic stapled BH3 peptides

granted A61KA61K31/635A61K38/00A61K38/10
Status granted
Linked drugs 3
Pipeline programs 1
Years to expiry 16
Applicant portfolio 163
Patent details — US 11312756
Jurisdiction
US
Status
granted
Grant date
Apr 26, 2022
Expiration
Apr 21, 2042
Claims
30
CPC classes
A61K, A61K31/635, A61K38/00, A61K38/10
View on Google Patents ↗

Quick answer

US 11312756 (Engineered potent cytotoxic stapled BH3 peptides) is held by THE TRUSTEES OF PRINCETON UNIVERSITY. Status: granted. Granted Apr 26, 2022. Expires Apr 21, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
30
CPC classes
A61K, A61K31/635, A61K38/00, A61K38/10, A61K38/12, A61K38/1761

More from THE TRUSTEES OF PRINCETON UNIVERSITY

Related pharmaceutical patents in our USPTO index.

  1. US 12419831

    Hydrocortisone oral liquid formulations

    Eton Pharmaceuticals, Inc. · Expires Sep 18, 2045

    granted
  2. US 12396974

    Ketone ester as a therapeutic treatment of Covid-19 and related viral infections

    KetoneAid · Expires Aug 21, 2045

    granted
  3. US 12357582

    Hydrophobic ion pairing and flash nanoprecipitation for formation of controlled-release nanocarrier formulations

    THE TRUSTEES OF PRINCETON UNIVERSITY · Expires Jul 10, 2045

    granted
  4. US 12343324

    Dihydromyricetin hot melt extrusion formulations and methods for forming them

    THE TRUSTEES OF PRINCETON UNIVERSITY · Expires Jun 26, 2045

    granted
  5. US 12329816

    Immunotherapy with metabolic enzyme expression

    THE TRUSTEES OF PRINCETON UNIVERSITY · Expires Jun 12, 2045

    granted
  6. US 12209256

    System for protein inactivation and recombinant phages for targeted bacterial killing, infection, biodetection, and as a means of protein extraction

    THE TRUSTEES OF PRINCETON UNIVERSITY · Expires Jan 23, 2045

    granted
  7. US 12195768

    System and method for modulating stress granule assembly

    THE TRUSTEES OF PRINCETON UNIVERSITY · Expires Jan 9, 2045

    granted
  8. US 12186436

    Triblock copolymer stabilizers for the formation of nanoparticles encapsulating soluble biologics, therapeutics, and imaging agents

    THE TRUSTEES OF PRINCETON UNIVERSITY · Expires Jan 2, 2045

    granted

Frequently asked questions

What is US patent 11312756?

US 11312756 (Engineered potent cytotoxic stapled BH3 peptides) is held by THE TRUSTEES OF PRINCETON UNIVERSITY. Status: granted. Granted Apr 26, 2022. Expires Apr 21, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11312756?

THE TRUSTEES OF PRINCETON UNIVERSITY is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 163 pharmaceutical patents for this assignee.

When does US 11312756 expire?

Our index shows an expiration date of Apr 21, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.